Spermotile

As infertility rates rise globally, affecting 15% of couples, the demand for ART (Assisted Reproduction Technologies) has increased. But ART is demanding — physically, psychologically, and financially — with no guarantee of success. Selecting the highest quality sperm for fertilization can improve ART outcomes.

At Spermotile, we’re pioneering a breakthrough in Assisted Reproductive Therapy (ART). Our focus is on identifying the highest quality ‘star sperms’ from semen samples for use in ART. With a flourishing family of intellectual properties, we’re now developing the Spermotile filtration system that ensures the best outcomes for fertility treatments.

We will spin out and be market ready in 2027. We are looking for partners (investment, fertility clinics, production, distribution, sales, etc.).